Immune Checkpoints: The Search for a Single Antiviral-Anticancer Magic Bullet

Khaled Barakat*

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada

Immune checkpoints constitute a distinctive set of proteins that belong to the B7 family. The engagement of these transmembrane receptors with their ligands provides critical signals to inhibit T cell activation and promote for immune tolerance. Tumor and infected cells can hide from the immune system by overexpressing these proteins, leading to T cell exhaustion [1]. Blocking these interactions emerged as a 'game changing' approach in anticancer and antiviral immunotherapy [2-4]. Current immune checkpoints blockers are limited to antibodies [5] and possess a unique mode of action; they reactivate exhausted T cells, allowing them to proliferate and recognize and kill infected and tumor cells [4,6]. Despite their outstanding success the ultimate therapeutic target, or combination of targets, from these proteins is still to be determined. The list of immune checkpoints is continuously growing and new effective targets are being frequently added [7]. In addition, very little is known about the underlying mechanisms that follow the engagement of these receptors with their ligands. For example, apart from the recruitment of tyrosine phosphatases to PD-1 (CD279) [8], the mechanism by which these interactions maintain T cell exhaustion is still a mystery. Furthermore, each receptor/ligand from this family can interact with more than one protein. For example, CTLA-4 (CD158) interacts with the two ligands, B7-1 (CD80) and B7-2 (CD86), promoting for T cell exhaustion. The same ligands stimulate T cells by interacting with a different receptor, CD28 [9,10]. Another example is the PD-1 receptor, which interacts with two different ligands, namely PD-L1 and PD-L2 [11,12]. On the other hand, the ligand PD-L1 also interacts with another ligand, B7-111. This small network of protein-protein interactions is a minute part of a more complex and intricate arrangement among the members of the B7 family of proteins. The complexity of this network requires a multidisciplinary effort that involves molecular and mathematical modelers [12-14], immunologists [15], structural and bioinformaticians, systems biologists, oncologists and many others to search for a magical combination of protein targets that can possibly lead to a complete clinical cure of chronic infection and malignant tumors.

A harmony among these different disciplines will not only identify the optimal combination of these therapeutic target(s), but can also help expand the current immune checkpoints' blocking agents beyond antibodies and use state-of-the-art technologies [13,16-23] to design small molecule inhibitors for these targets [12]. Take the PD-1, CTLA-4 and TIM-3 pathways as an example. Currently, these are the leading immune checkpoints targets, particularly, for advanced metastatic melanoma. One important aspect in prioritizing or combining these targets is their expression level in the host. A widely expressed checkpoint molecule could promote autoimmune-like side effects. For example, CTLA-4 is up-regulated on all effector T cells and is also expressed on all regulatory T cells (Tregs). Consequently, blockade of CTLA-4 could disrupt CTLA-4–driven regulation of effector T-cell responses or interfere with the function and/or number of Tregs, as has been suggested by recent studies [24-26]. Although PD-1 is similarly up-regulated on all effector T cells, autoimmune-like toxicities have been observed in a lower scale relative to CTLA-4 in patients treated with anti–PD-1 antibodies [27,28]. TIM-3, however, is not expressed on all T cells; rather, it is selectively expressed on T cells that have differentiated toward an IFN-g–producing phenotype [29], and in patients with cancer, TIM-3 seems to be expressed primarily in intratumoral T cells [30]. TIM-3–deficient mice do not exhibit autoimmunity [31], unlike both CTLA-4 deficient [9,10] and PD-1–deficient mice [32]. Thus, from an expression point of view, TIM-3 blockade is favored over CTLA-4 or PD-1. However, another important aspect in prioritizing these targets is the available structural and experimental data that can help in rationally design blocking inhibitors for these proteins. In this regard, CTLA-4 can be ranked first as it is the most understood pathway and with the most structural information available. Structurally and mechanistically, TIM-3 is ranked last relative to both PD-1 and CTLA-4, since there are only two crystal structures for the unbound mouse variant and the TIM-3 pathway is relatively new and not well understood. Although the structural information for PD-1 is not as comprehensive as that of CTLA-4, available data can be used to understand how these molecules interact in human. Taken together and although we raised here more questions rather than answers, it seems that the concept of blocking the immune checkpoints is still in its infancy and more efforts are needed to fully exploit this very new and exiting area of research toward a magic bullet for cancer and chronic infectious diseases.

References

1. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH (2006) Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203: 2223-2227.

2. Merelli B, Massi D, Cattaneo L, Mandala M (2014) Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Critical reviews in oncology/hematology 89: 140-165.

3. Domling A, Holak TA (2014) Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angewandte Chemie 53: 2286-2288.

4. Intlekofer AM, Thompson CB (2013) At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Journal of leukocyte biology 94: 25-39.

5. Barakat K (2014) Do We Need Small Molecule Inhibitors for the Immune Checkpoints? J Pharma Care Health Sys 1: 1000e119.

6. Cooper LJN, Vence LM, Maiti S, Rabinovich B, Zhang M, et al. (2012) A new approach to simultaneously quantify both TCR alpha- and beta-chain diversity after adoptive immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 18: 4733-4742.

*Corresponding author: Khaled Barakat, Research Assistant Professor, University of Alberta, University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences, 02-20G Katz Centre, Edmonton, AB, T6G 2E1, Canada, Tel: 1 780-492- 5783; E-mail: kbarakat@ualberta.ca

7. Chen YS, Shen CR (2015) Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science. Biomed J 38: 5-8.

8. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954.

9. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.

10. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.

11. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.

12. Viricel C, Ahmed M, Barakat K (2015) Human PD-1 Binds Differently To Its Human Ligands: A Comprehensive Modelling Study. J Mol Graphics Mod 57: 131-142.

13. Jordheim LP, Barakat KH, Balard HL, Matera EL, Cros-Perrial E, et al. (2013) Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 84: 12-24.

14. Barakat KH, Law J, Prunotto A, Magee WC, Evans DH, et al. (2013) Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design. J Chem Inf Model 53: 3031-3043.

15. Egli A, Levin A, Santer DM, Joyce M, O'Shea D, et al. (2014) Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 210: 717-727.

16. Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, et al. (2012) Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One 7: e51329.

17. Friesen DE, Barakat KH, Semenchenko V, Perez-Pineiro R, Fenske BW, et al. (2012) Discovery of small molecule inhibitors that interact with Iᵃ-tubulin. Chem Biol Drug Des 79: 639-652.

18. Barakat KH, Mohamed AA, Tuszynski JA, Robins MJ, Tyrrell DL, et al. (2014) A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes. J Chem Inf Model 55: 362-373.

19. Hu G, Wang K, Groenendyk J, Barakat K, Mizianty MJ, et al. (2014) Human structural proteome-wide characterization of Cyclosporine A targets. Bioinformatics 30: 3561-3566.

20. Anwar-Mohamed A, Barakat KH, Bhat R, Noskov SY, Tyrrell DL, et al. (2014) A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicol Lett 230: 382-392.

21. Barakat KH, Houghton M, Tyrrel DL, Tuszynski JA (2014) Rational Drug Design: One Target, Many Paths to It 4: 59-85.

22. Barakat K (2014) Computer-Aided Drug Design. J Pharma Care Health Sys 1: 1000e113.

23. Barakat K, Tuszynski J (2011) Virtual Screening for DNA Repair Inhibitors in DNA Repair - On the Pathways to Fixing DNA Damage and Errors 1: 287-312.

24. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, et al. (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer immunology research 1: 32-42.

25. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, et al. (2013) Activating Fc Iᵃ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210: 1685-1693.

26. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210: 1695-1710.

27. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.

28. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144.

29. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.

30. Gao X, Zhu Y, Li G, Huang H, Zhang G, et al. (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 7: e30676.

31. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102-1110.

32. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.